A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease
Latest Information Update: 04 Jan 2025
At a glance
- Drugs Alemtuzumab (Primary) ; Sirolimus (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Jun 2024 Planned End Date changed from 26 Oct 2028 to 1 Dec 2026.
- 16 Jun 2024 Planned primary completion date changed from 26 Oct 2028 to 1 Dec 2026.
- 07 Jun 2022 Status changed from not yet recruiting to recruiting.